

Changmeng Cai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6559322/publications.pdf>

Version: 2024-02-01

44
papers

3,826
citations

236912

25
h-index

243610

44
g-index

45
all docs

45
docs citations

45
times ranked

6021
citing authors

#	ARTICLE	IF	CITATIONS
1	EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent. <i>Science</i> , 2012, 338, 1465-1469.	12.6	748
2	Androgen Receptor Gene Expression in Prostate Cancer Is Directly Suppressed by the Androgen Receptor Through Recruitment of Lysine-Specific Demethylase 1. <i>Cancer Cell</i> , 2011, 20, 457-471.	16.8	387
3	Intratumoral <i>De Novo</i> Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 Inhibitors. <i>Cancer Research</i> , 2011, 71, 6503-6513.	0.9	383
4	ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer. <i>Journal of Clinical Investigation</i> , 2013, 123, 1109-1122.	8.2	227
5	Rapid Induction of Androgen Receptor Splice Variants by Androgen Deprivation in Prostate Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 1590-1600.	7.0	165
6	Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen Receptors. <i>Clinical Cancer Research</i> , 2015, 21, 1273-1280.	7.0	152
7	Reactivation of Androgen Receptor-Regulated <i>TMPRSS2:ERG</i> Gene Expression in Castration-Resistant Prostate Cancer. <i>Cancer Research</i> , 2009, 69, 6027-6032.	0.9	141
8	SOX9 drives WNT pathway activation in prostate cancer. <i>Journal of Clinical Investigation</i> , 2016, 126, 1745-1758.	8.2	138
9	Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. <i>Endocrine-Related Cancer</i> , 2011, 18, R175-R182.	3.1	131
10	Lysine-Specific Demethylase 1 Has Dual Functions as a Major Regulator of Androgen Receptor Transcriptional Activity. <i>Cell Reports</i> , 2014, 9, 1618-1627.	6.4	115
11	ETV1 Is a Novel Androgen Receptor-Regulated Gene that Mediates Prostate Cancer Cell Invasion. <i>Molecular Endocrinology</i> , 2007, 21, 1835-1846.	3.7	104
12	Androgen Receptor Serine 81 Phosphorylation Mediates Chromatin Binding and Transcriptional Activation. <i>Journal of Biological Chemistry</i> , 2012, 287, 8571-8583.	3.4	94
13	Galeterone Prevents Androgen Receptor Binding to Chromatin and Enhances Degradation of Mutant Androgen Receptor. <i>Clinical Cancer Research</i> , 2014, 20, 4075-4085.	7.0	81
14	Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer. <i>Nature Genetics</i> , 2020, 52, 1011-1017.	21.4	78
15	Pioneer of prostate cancer: past, present and the future of FOXA1. <i>Protein and Cell</i> , 2021, 12, 29-38.	11.0	77
16	LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression. <i>Cancer Research</i> , 2017, 77, 5479-5490.	0.9	71
17	Androgen Receptor Tumor Suppressor Function Is Mediated by Recruitment of Retinoblastoma Protein. <i>Cell Reports</i> , 2016, 17, 966-976.	6.4	66
18	Androgen Receptor Enhances p27 Degradation in Prostate Cancer Cells through Rapid and Selective TORC2 Activation. <i>Journal of Biological Chemistry</i> , 2012, 287, 2090-2098.	3.4	63

#	ARTICLE	IF	CITATIONS
19	Androgen Receptor Expression in Prostate Cancer Cells Is Suppressed by Activation of Epidermal Growth Factor Receptor and ErbB2. <i>Cancer Research</i> , 2009, 69, 5202-5209.	0.9	48
20	PLZF, a Tumor Suppressor Genetically Lost in Metastatic Castration-Resistant Prostate Cancer, Is a Mediator of Resistance to Androgen Deprivation Therapy. <i>Cancer Research</i> , 2015, 75, 1944-1948.	0.9	46
21	SUMO-3 Enhances Androgen Receptor Transcriptional Activity through a Sumoylation-independent Mechanism in Prostate Cancer Cells. <i>Journal of Biological Chemistry</i> , 2006, 281, 4002-4012.	3.4	41
22	Discovery of a Selective Irreversible BMX Inhibitor for Prostate Cancer. <i>ACS Chemical Biology</i> , 2013, 8, 1423-1428.	3.4	40
23	ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 3672-3682.	7.0	39
24	Makorin RING Finger Protein 1 (MKRN1) Has Negative and Positive Effects on RNA Polymerase II-Dependent Transcription. <i>Endocrine</i> , 2006, 29, 363-374.	2.2	30
25	c-Jun Has Multiple Enhancing Activities in the Novel Cross Talk between the Androgen Receptor and Ets Variant Gene 1 in Prostate Cancer. <i>Molecular Cancer Research</i> , 2007, 5, 725-735.	3.4	29
26	TMPRSS2-ERG activates NO-cGMP signaling in prostate cancer cells. <i>Oncogene</i> , 2019, 38, 4397-4411.	5.9	29
27	Positive feedback loop mediated by protein phosphatase 1 \pm mobilization of P-TEFb and basal CDK1 drives androgen receptor in prostate cancer. <i>Nucleic Acids Research</i> , 2017, 45, gkw1291.	14.5	28
28	Forkhead domain mutations in FOXA1 drive prostate cancer progression. <i>Cell Research</i> , 2019, 29, 770-772.	12.0	25
29	In Silico Discovery of Androgen Receptor Antagonists with Activity in Castration Resistant Prostate Cancer. <i>Molecular Endocrinology</i> , 2012, 26, 1836-1846.	3.7	22
30	Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	22
31	Tyrosine Kinase BMX Phosphorylates Phosphotyrosine-Primed Motif Mediating the Activation of Multiple Receptor Tyrosine Kinases. <i>Science Signaling</i> , 2013, 6, ra40.	3.6	21
32	Soluble Guanylyl Cyclase \pm 1 and p53 Cytoplasmic Sequestration and Down-Regulation in Prostate Cancer. <i>Molecular Endocrinology</i> , 2012, 26, 292-307.	3.7	20
33	Protein phosphatase 1 suppresses androgen receptor ubiquitylation and degradation. <i>Oncotarget</i> , 2016, 7, 1754-1764.	1.8	20
34	ZBTB7A Mediates the Transcriptional Repression Activity of the Androgen Receptor in Prostate Cancer. <i>Cancer Research</i> , 2019, 79, 5260-5271.	0.9	19
35	Androgen receptor epigenetics. <i>Translational Andrology and Urology</i> , 2013, 2, 148-157.	1.4	19
36	RB1 loss in castration-resistant prostate cancer confers vulnerability to LSD1 inhibition. <i>Oncogene</i> , 2022, 41, 852-864.	5.9	18

#	ARTICLE	IF	CITATIONS
37	Exploiting AR-Regulated Drug Transport to Induce Sensitivity to the Survivin Inhibitor YM155. <i>Molecular Cancer Research</i> , 2017, 15, 521-531.	3.4	17
38	BMX-Mediated Regulation of Multiple Tyrosine Kinases Contributes to Castration Resistance in Prostate Cancer. <i>Cancer Research</i> , 2018, 78, 5203-5215.	0.9	16
39	LSD1 Activates PI3K/AKT Signaling Through Regulating p85 Expression in Prostate Cancer Cells. <i>Frontiers in Oncology</i> , 2019, 9, 721.	2.8	14
40	Expression of a hyperactive androgen receptor leads to androgen-independent growth of prostate cancer cells. <i>Journal of Molecular Endocrinology</i> , 2008, 41, 13-23.	2.5	12
41	Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer. <i>Molecular Therapy</i> , 2022, 30, 1628-1644.	8.2	10
42	A novel nonsense mutation in androgen receptor confers resistance to CYP17 inhibitor treatment in prostate cancer. <i>Oncotarget</i> , 2017, 8, 6796-6808.	1.8	8
43	A Novel Mechanism to Induce BRCAness in Cancer Cells. <i>Cancer Research</i> , 2020, 80, 2977-2978.	0.9	7
44	Susceptibility-Associated Genetic Variation in <i>NEDD9</i> Contributes to Prostate Cancer Initiation and Progression. <i>Cancer Research</i> , 2021, 81, 3766-3776.	0.9	4